(±)17(18)-EpETE-Ethanolamide

(±)17(18)-EpETE-Ethanolamide Suppliers list
Company Name: Shanghai Hongye Biotechnology Co. Ltd  
Tel: 400-9205774
Email: sales@glpbio.cn
Products Intro: Product Name:(±)17(18)-EpETE-Ethanolamide
CAS:2123491-23-4
Purity:>98% Package:1mg;10mg;50mg;100mg;
Company Name: ChemeGen(Shanghai) Biotechnology Co.,Ltd.  
Tel: 18818260767
Email: sales@chemegen.com
Products Intro: Product Name:(±)17(18)-EpETE-Ethanolamide
CAS:2123491-23-4
Purity:98% Package:10 mg;50 mg;100 mg;500 mg;1 g;5 g;10 g
Company Name: Shanghai Yifei Biotechnology Co. , Ltd.  
Tel: 021-65675885 18964387627
Email: customer_service@efebio.com
Products Intro: Product Name:(±)17(18)-EpETE-Ethanolamide
CAS:2123491-23-4
Purity:98% Package:25μg;50μg;100μg
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
Products Intro: Product Name:(±)17(18)-EpETE-Ethanolamide
CAS:2123491-23-4
Package:50mg;10mg
Company Name: Cayman Chemical Company  
Tel: (800) 364-9897
Email: cayman@caymanchem.com
Products Intro: Product Name:(±)17(18)-EpETE-Ethanolamide
CAS:2123491-23-4
(±)17(18)-EpETE-Ethanolamide Basic information
Product Name:(±)17(18)-EpETE-Ethanolamide
Synonyms:(±)17(18)-EpETE-Ethanolamide;5,8,11,14-Hexadecatetraenamide, 16-(3-ethyl-2-oxiranyl)-N-(2-hydroxyethyl)-, (5Z,8Z,11Z,14Z)-
CAS:2123491-23-4
MF:C22H35NO3
MW:361.52
EINECS:
Product Categories:
Mol File:2123491-23-4.mol
(±)17(18)-EpETE-Ethanolamide Structure
(±)17(18)-EpETE-Ethanolamide Chemical Properties
Boiling point 547.7±50.0 °C(Predicted)
density 1.000±0.06 g/cm3(Predicted)
storage temp. Store at -20°C
solubility DMF: 30 mg/ml; DMSO: 25 mg/ml; Ethanol: 30 mg/ml
pka14.48±0.10(Predicted)
Safety Information
MSDS Information
(±)17(18)-EpETE-Ethanolamide Usage And Synthesis
Description(±)17(18)-EpETE-Ethanolamide is an ω-3 endocannabinoid epoxide.1 It is formed from the endocannabinoid eicosapentaenoic ethanolamide (EPEA) via cytochrome P450 (CYP) epoxygenases and hydrolyzed by soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH). It is endogenously produced in LPS-stimulated BV-2 microglia cells and in BV-2 microglia cells supplemented with EPEA, an effect that can be reduced by the CYP inhibitor ketoconazole. (±)17(18)-EpETE-ethanolamide decreases IL-6 and nitrite production induced by LPS in BV-2 microglia and increases the production of IL-10. It inhibits platelet aggregation induced by arachidonic acid when used at a concentration of 50 μM but not aggregation induced by ADP , collagen, or ristocetin. It also induces relaxation of preconstricted bovine coronary arteries (ED50 = 1.1 μM) and inhibits VEGF-stimulated tubulogenesis in human microvascular endothelial cells (HMVECs). (±)17(18)-EpETE-ethanolamide is the predominant EPEA metabolite found in rat brain, and it has also been found in rat heart, kidney, spleen, and liver, as well as in pig brain. It activates cannabinoid receptor 1 (CB1) and CB2 with EC50 values of 18.5 and 1.4 nM, respectively, in a β-arrestin recruitment assay.
References1. McDougle, D.R., Watson, J.E., Abdeen, A.A., et al. Anti-inflammatory ω-3 endocannabinoid epoxides Proc. Natl. Acad. Sci. USA 114(30),E6034-E6043(2017).
(±)17(18)-EpETE-Ethanolamide Preparation Products And Raw materials
Tag:(±)17(18)-EpETE-Ethanolamide(2123491-23-4) Related Product Information